Jan H.M. Schellens
0000-0001-6832-1976
Publication & Citation Trends
Publications
0 total
Bone Toxicity Case Report Combining Encorafenib, Cetuximab and WNT974 in a Phase I Trial
Cited by 1
Semantic Scholar
First-in-Human Dose-Escalation and -Expansion Trial with Sirpα Antibody BYON4228 in R/R B-Cell NHL OA
Cited by 3
Semantic Scholar
A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma OA
Cited by 23
Semantic Scholar
Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations. OA
Cited by 26
Semantic Scholar
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. OA
Cited by 358
Semantic Scholar
Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study OA
Cited by 2
Semantic Scholar
Abstract CT103: Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: Preliminary results from KEYNOTE-028
Cited by 45
Semantic Scholar
AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies OA
Cited by 46
Semantic Scholar
Research Topics
Colorectal Cancer Treatments and Studies
(231)
Cancer Treatment and Pharmacology
(221)
Cancer therapeutics and mechanisms
(161)
Drug Transport and Resistance Mechanisms
(127)
Lung Cancer Treatments and Mutations
(125)
Affiliations
AstraZeneca (United Kingdom)
Roche (Switzerland)
Leiden University
Hebron University
Uppsala University